Protease-independent control of parthanatos by HtrA2/Omi

被引:2
|
作者
Weiss, Jonas [1 ]
Heib, Michelle [1 ]
Korn, Thiemo [1 ]
Hoyer, Justus [1 ]
Fuchslocher Chico, Johaiber [1 ]
Voigt, Susann [1 ]
Koudelka, Tomas [2 ]
Tholey, Andreas [2 ]
Adam, Dieter [1 ]
机构
[1] Christian Albrechts Univ Kiel, Inst Immunol, Michaelisstr 5, D-24105 Kiel, Germany
[2] Christian Albrechts Univ Kiel, Inst Expt Med, Niemannsweg 11, D-24105 Kiel, Germany
关键词
HtrA2; Omi; Parthanatos; Proteolysis; Cell death; APOPTOSIS-INDUCING FACTOR; PROMOTES CELL-DEATH; SERINE-PROTEASE; POLY(ADP-RIBOSE) POLYMERASE; OMI/HTRA2; PROTEASE; CALPAIN-I; ACTIVATION; INHIBITOR; BINDING; MITOCHONDRIA;
D O I
10.1007/s00018-023-04904-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HtrA2/Omi is a mitochondrial serine protease with ascribed pro-apoptotic as well as pro-necroptotic functions. Here, we establish that HtrA2/Omi also controls parthanatos, a third modality of regulated cell death. Deletion of HtrA2/Omi protects cells from parthanatos while reconstitution with the protease restores the parthanatic death response. The effects of HtrA2/Omi on parthanatos are specific and cannot be recapitulated by manipulating other mitochondrial proteases such as PARL, LONP1 or PMPCA. HtrA2/Omi controls parthanatos in a manner mechanistically distinct from its action in apoptosis or necroptosis, i.e., not by cleaving cytosolic IAP proteins but rather exerting its effects without exiting mitochondria, and downstream of PARP-1, the first component of the parthanatic signaling cascade. Also, previously identified or candidate substrates of HtrA2/Omi such as PDXDC1, VPS4B or moesin are not cleaved and dispensable for parthanatos, whereas DBC-1 and stathmin are cleaved, and thus represent potential parthanatic downstream mediators of HtrA2/Omi. Moreover, mass-spectrometric screening for novel parthanatic substrates of HtrA2/Omi revealed that the induction of parthanatos does not cause a substantial proteolytic cleavage or major alterations in the abundance of mitochondrial proteins. Resolving these findings, reconstitution of HtrA2/Omi-deficient cells with a catalytically inactive HtrA2/Omi mutant restored their sensitivity against parthanatos to the same level as the protease-active HtrA2/Omi protein. Additionally, an inhibitor of HtrA2/Omi's protease activity did not confer protection against parthanatic cell death. Our results demonstrate that HtrA2/Omi controls parthanatos in a protease-independent manner, likely via novel, unanticipated functions as a scaffolding protein and an interaction with so far unknown mitochondrial proteins.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Protease-independent control of parthanatos by HtrA2/Omi
    Jonas Weiß
    Michelle Heib
    Thiemo Korn
    Justus Hoyer
    Johaiber Fuchslocher Chico
    Susann Voigt
    Tomas Koudelka
    Andreas Tholey
    Dieter Adam
    Cellular and Molecular Life Sciences, 2023, 80
  • [2] Specific protein interaction of human Pag with Omi/HtrA2 and the activation of the protease activity of Omi/HtrA2
    Hong, SK
    Cha, MK
    Kim, IH
    FREE RADICAL BIOLOGY AND MEDICINE, 2006, 40 (02) : 275 - 284
  • [3] The mitochondrial serine protease HtrA2/Omi: an overview
    L Vande Walle
    M Lamkanfi
    P Vandenabeele
    Cell Death & Differentiation, 2008, 15 : 453 - 460
  • [4] The mitochondrial serine protease HtrA2/Omi: an overview
    Vande Walle, L.
    Lamkanfi, M.
    Vandenabeele, P.
    CELL DEATH AND DIFFERENTIATION, 2008, 15 (03): : 453 - 460
  • [5] A novel role for the mitochondrial HTRA2/OMI protease in aging
    Kang, Seokwon
    Fernandes-Alnemri, Teresa
    Alnemri, Emad S.
    AUTOPHAGY, 2013, 9 (03) : 420 - 421
  • [6] Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferation
    Kuninaka, S.
    Iida, S-I
    Hara, T.
    Nomura, M.
    Naoe, H.
    Morisaki, T.
    Nitta, M.
    Arima, Y.
    Mimori, T.
    Yonehara, S.
    Saya, H.
    ONCOGENE, 2007, 26 (17) : 2395 - 2406
  • [7] Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferation
    S Kuninaka
    S-I Iida
    T Hara
    M Nomura
    H Naoe
    T Morisaki
    M Nitta
    Y Arima
    T Mimori
    S Yonehara
    H Saya
    Oncogene, 2007, 26 : 2395 - 2406
  • [8] Mitochondrial Serine Protease HtrA2/Omi as a Potential Therapeutic Target
    Bhuiyan, Md. Shenuarin
    Fukunaga, Kohji
    CURRENT DRUG TARGETS, 2009, 10 (04) : 372 - 383
  • [9] Proteasome Inhibitors Do Not Inhibit the Serine Protease HtrA2/Omi
    Senn, Joseph
    Csizmadia, Vilmos
    Hales, Paul
    Dick, Larry
    Kadambi, Vivek J.
    BLOOD, 2012, 120 (21)
  • [10] Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases
    Goo, Hui-Gwan
    Rhim, Hyangshuk
    Kang, Seongman
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2017, 18 (07) : 746 - 757